FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures and PharmaTelevision CEO Fintan Walton. The interview, conducted during BIO 2012 in Boston, reflects Fraher’s commentary regarding the integration of companies post Axcan Intermediate Holdings’ acquisition of Eurand NV in 2011.
The interview is available on-demand at PharmaTelevision from Wednesday, 5 September 2012 and also will be available to the public at the Aptalis Pharmaceutical Technologies website. Fraher serves a key role in setting strategic direction for Aptalis with specific oversight of the company’s Pharmaceutical Technologies and Global Supply Chain business unit. PharmaTelevision is an online TV channel for the biopharma industry offering feature interviews with industry leaders, analysis and a television news archive.
Visit www.AptalisPharmaTech.com
Approximately one year ago PharmaTelevison conducted its first interview with Fraher just a few months after Axcan completed its acquisition of Eurand NV. During the months following the acquisition, the companies completed their integration while realizing several major milestones including FDA approvals, the in-licensing of a number of products and a closing-year revenue of $470m – a significant increase on the prior year. During his BIO 2012 interview with PharmaTelevision, Fraher discusses these milestones and the company’s strategic direction moving forward.